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ABSTRACT
Recently, research has been deeply focusing on the role of the microbiota in numerous diseases,
either affecting the skin or other organs. What it is well established is that its dysregulation pro-
motes several cutaneous disorders (i.e. psoriasis and atopic dermatitis). To date, little is known
about its composition, mediators and role in the genesis, progression and response to therapy
of Non-Melanoma Skin Cancer (NMSC). Starting from a bibliographic study, we classified the
selected articles into four sections: i) normal skin microbiota; ii) in vitro study models; iii) micro-
biota and NMSC and iv) probiotics, antibiotics and NMSC. What has emerged is how skin micro-
flora changes, mainly represented by increases of Staphylococcus aureus, Streptococcus pyogenes
and Pseudomonas aeruginosa strains, modifications in the mutual quantity of b-Human papillo-
mavirus genotypes, of Epstein Barr Virus and Malassezia or candidiasis, may contribute to the
induction of a state of chronic self-maintaining inflammation, leading to cancer. In this context,
the role of S. aureus and that of specific antimicrobial peptides look to be prominent. Moreover,
although antibiotics may contribute to carcinogenesis, due to their ability to influence the micro-
biota balance, specific probiotics, such as Lacticaseibacillus rhamnosus GG, Lactobacillus johnsonii
NCC 533 and Bifidobacteria spp., may be protective.
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In the last years, numerous studies highlighting the
relationship between microbiota and melanoma have
been published (Yan et al. 2018; Gong et al. 2019;
Smibert et al. 2019). Indeed, the crucial role of immune
checkpoint inhibitors in improving the prognosis of
melanoma patients is confirmed, and the hypothesis
that the antitumor response to the anti-CTLA-4 and PD-
1 monoclonal antibodies is dependent on the intestinal
microbiota is supported by a lot of evidence (Vetizou
et al. 2015; Dong et al. 2018; Gopalakrishnan et al. 2018;
Humphries and Daud 2018; Matson et al. 2018; Chaput
et al. 2019; Li et al. 2019). On the contrary, the relation-
ship between the cutaneous microbiota and NMSC is
poorly known, despite the high frequency of this neo-
plasm and the clear role of the immune system in its
pathogenesis, evident from its increased occurrence
and aggressiveness among immunosuppressed patients
(Howard et al. 2018; Zavattaro et al. 2019).
In this paper, starting from a careful revision of the
scientific literature, we tried to highlight the possible
role of the microbiota in the pathogenesis of skin
tumours of keratinocyte origin and its potential prog-
nostic and therapeutic implications.
Methods
A bibliographic research analysis was performed in the
archives of PubMedCentralVR , looking for international
original peer-reviewed articles published in the English
language in the time frame ranging from January 2000
to February 2020. The following terms were searched as
inclusion criteria, single and/or combined, to look
for the most pertinent abstracts: “microbiota”,
“microbiome”, “bacteriota”, “bacteria”, “dysbiosis”,
“antibiotics”, “probiotics”, “study models”, “skin
immunity”, “skin microenvironment”, “Non-Melanoma
Skin Cancer (NMSC)”, “Basal Cell Carcinoma (BCC)”,
Squamous Cell Carcinoma (SCC)”, “skin cancer risk
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factors”, “Staphylococcus aureus”, “Staphylococcus epi-
dermidis” , “virota”, “virome”, “virus”, “beta Human
Papillomavirus (b-HPV)”, “Epstein- Barr virus (EBV)”,
“fungiota”, “mycobiota”, “fungi”, “mycetes”,
“Candida spp”.
Both original and review articles (human, animal,
and cell studies) and their bibliographies were analysed.
Studies in languages other than English, meeting
abstracts and posters were excluded. We found a total
of about five hundred and thirty papers. After deep
reading and revision, we reported the one hundred and
sixty-six relevant and pertinent to the pre-established
admissibility criteria and classified them into four cate-
gories including i) normal skin microbiota; ii) in vitro
study models; iii) microbiota and NMSC; iv) probiotics,
antibiotics and NMSC.
The human skin microbiota
The skin is the largest interface and interactive organ of
the human body. Its squamous pluristratified epithelial
surface, composed of an external flat area and an inner
part comprising about 5 million appendages, such as
hair follicles and sweat ducts (Gallo 2017), makes it fully
accessible to a plethora of microorganisms.
Thanks to the Human Microbiome Project (HMP),
their complexity and variety started to be characterised
since about 13 years by the National Institute of Health
(NIH) (Sanford and Gallo 2013). Worldwide research
studies have thus evidenced that one hundred trillion
microbes, possessing 1,000 times more genes than
humans and comprising bacteria, viruses, phages and
fungi essential to the host immunity’s welfare, reside in
different body niches including the skin (Weinstock
2012). Among them, on the skin resides a core of resili-
ent commensals together with transient microbes, both
non-pathogenic in normal conditions, that perform key
functions and that may change, as a consequence of
chronic UV exposure as well in the course of numerous
diseases, including NMSC (Figure 1) (Dreno et al. 2016;
Fyhrquist et al. 2016; Abdallah et al. 2017; Strickley
et al. 2019).
In particular, cutaneous bacterial microorganisms
inhibit pathogens invasion through amphipathic consti-
tutive or upregulated antimicrobial peptides (AMPs),
such as the cathelicidin LL-37 and human b-defensins
(i.e. hBD-1, 2 and 3 and the antimicrobial RNase 7
protein), which stimulate keratinocyte-derived innate
and adaptive immune mediators, by acting on their
training and maintenance, in both the epidermal and
dermal compartments (Wanke et al. 2011; Chen et al.
2018). The crosstalk among primary human keratino-
cytes, immune cells and microorganisms, regulated by
AMPs, cytokines and chemokines, is essential for skin
integrity (Grice and Segre 2011).
To contribute to skin microbiota preservation, epi-
thelial surface desquamation, which cyclically occurs
during the renewal process, as well as acid pH, inhibits
Figure 1. Non-pathogenic and altered microbiota in normal and UV-exposed NMSC-affected skin.
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the growth of pathogens competing for nutrients
(Candi et al. 2005; Borkowski and Gallo 2011; Coates
et al. 2018). Accordingly, different factors (i.e. skincare
products, smoking) could be responsible for microbiota
variations (Gallo and Nakatsuji 2011; Bouslimani et al.
2019; Thompson et al. 2020).
Healthy microbiota alterations have been linked with
several different diseases, including allergy, obesity,
inflammatory bowel disease (IBD), diabetes mellitus,
metabolic syndrome, and brain disorder; moreover,
while the skin microbiota’s influence on acne vulgaris,
rosacea, atopic dermatitis (AD) and psoriasis (Gallo and
Nakatsuji 2011; Salava and Lauerma 2014; Chang et al.
2018; Langan et al. 2018; Sun et al. 2019) has been
demonstrated, only a few studies have been published
on NMSC (Squarzanti et al. 2019).
In addition, while the role of gut microbiota in vari-
ous diseases has been deeply investigated, studies
focussed on the cutaneous counterpart are less numer-
ous (Zeeuwen et al. 2013; Weyrich et al. 2015; Musthaq
et al. 2018; Dreno 2019).
Indeed, research conducted worldwide has evi-
denced how skin and gut microbiota are very different:
the skin is rich in Actinobacteria, while the gut is mostly
dominated by Firmicutes and Bacteroidetes (Grice and
Segre 2011). Conversely, they both possess a high
intra-individual variability over time (Costello et al.
2009; Wu et al. 2020). On the other hand, in recent
years, the existence of a connection between skin and
gut has been investigated and a close relationship
between the “gut-skin” and the “gut-brain” axes has
been supposed, thus leading to the term “gut-brain-
skin axis”. Indeed, despite some dermatological dis-
eases are frequently associated with gut bacterial over-
growth (also named “dysbiosis”), the gut can exert
different effects on the autonomic nervous system as
well as through neuro-endocrine pathway, contributing
in the pathogenesis of different skin dermatoses (Arck
et al. 2010). Among the other dermatoses, acne repre-
sents a paradigmatic disease that has been fully
studied and universally accepted to be aggravated by
gut microbiota’s change due to psychological stressors
(O’Neill et al. 2016; Lee et al. 2019).
Despite the use of advanced technologies and
similarly to the gut microbiota, it is difficult to define
the “healthy skin microbiota”, since it depends on the
individual eubiotic microbial community’s ability to
resist against pathogens colonisation (Costello
et al. 2009).
What it is known, is that commensal Staphylococcal
species regulate skin inflammation, via lipoteichoic acid
production, through a Toll-like receptor 3-dependent
pathway (Lai et al. 2009) thus activating the skin innate
immunity response (Dreno et al. 2016).
As an example, to maintain skin health, S. epidermidis
generally produces phenol-soluble modulins (Cogen
et al. 2010), but when a dysbiosis occurs, due to UV
over-exposure, genetic predisposition, diet errors, skin-
care products, drugs or indiscriminate antibiotic use,
this bacterium, as many others, is lost and the infection
risk is enhanced (Gallo and Nakatsuji 2011; Cundell
2018). Staphylococcal species are also reported in
different cutaneous diseases: indeed, AD is linked to
abundant S. aureus colonisation on both lesional and
non-lesional skin in adults, while in 12months AD
affected infants this colonisation is absent (Kennedy
et al. 2017). Moreover, chronic wounds are associated
with continuous inflammation due to bacterial invasion,
mainly by S. aureus, S. pyogenes, Enterococcus spp. or
Pseudomonas aeruginosa (P. aeruginosa) (Grice and
Segre 2011). As above described, S. aureus, common
skin commensal, is localised in parts of the body with a
high degree of humidity, preferring the groyne, the skin
folds, the popliteal fossa and the nose (Grice and Segre
2011). It usually doesn’t cause infections in immuno-
competent people unless it contacts injured skin after
surgery or traumas (Todd 2005) that can favour its
colonisation.
Based on 16S ribosomal RNA gene sequencing, four
main phyla (Actinobacteria, Firmicutes, Proteobacteria,
and Bacteroidetes) and three most common genera
(Corynebacteria, Propionibacteria, and Staphylococci)
have been described as major skin commensals (Grice
et al. 2009). In fact, in moist areas (navel, axilla, groyne,
sole, antecubital and popliteal fossa) Staphylococcus
and Corynebacterium species, belonging to the
Firmicutes and Actinobacteria phyla respectively, are
dominant; regarding the sebaceous areas (forehead,
alar crease, retro-auricular crease, back),
Propionibacteria species of the Actinobacteria phylum
have been isolated, probably due to their ability to
grow in anaerobic and lipid-rich environments; finally,
dry areas, such as forearm, hand, and buttocks, show
the major diversity with all the four phyla well repre-
sented (Sanford and Gallo 2013).
The study published by Grice et al. demonstrated
that Proteobacteria are the most abundant in all col-
lected skin samples, starting from the swabs and the
scrapes till the punch biopsies (Grice et al. 2008).
Moreover, as depicted by Nakatsuji et al. bacteria are
detected not only on the skin surface but also within
tissues, such as the dermal and adipose ones previously
considered as sterile, where they directly interact with
different cell types (Nakatsuji et al. 2013). For example,
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in the deeper layers of the skin, the bacteria contacts
with dendritic cells promote i) the production of IL-1,
IL-17, and IFN-c by T-cells, which migrate into the epi-
dermis, ii) the activation of natural killer (NK) cells, and
iii) the keratinocytes-mediated AMPs secretion (Egert
et al. 2017). Furthermore, microbiota colonisation is also
conditioned by the different oxygen tension between
the epithelial surface and the deeper layers (Grice et al.
2008; Zeeuwen et al. 2012; Nakatsuji et al. 2013).
Although bacteria are the most represented organ-
isms in the skin microbiota, fungi are also present. The
fungal microbiota, named Mycobiota, is mainly repre-
sented by Malassezia species in healthy skin, albeit
Candida, Aspergillus, Cryptococcus, Rhodotorula and
Epicoccum species have also been reported (Byrd et al.
2018; Sohn 2018). The fungi’s distribution over the
body is determined by the characteristics either of the
microorganisms or of the skin (body site, age, gender).
Indeed, since Malassezia species lack the fatty acid syn-
thase gene, they need the host’s long-chain fatty acids
to grow; consequently, they are mainly found in lipid-
rich cutaneous sites (i.e. face, scalp) (Findley and Grice
2014; Limon et al. 2017). Malassezia is believed to play
a role not only in the pathogenesis of pityriasis versicol-
our but also in inflammatory skin diseases, such as seb-
orrhoeic dermatitis, atopic dermatitis and psoriasis, in
which an exaggerated immune response to this yeast
type is detected (Jo et al. 2017). Recently, Li et al. have
characterised the Protease 1 produced by Malassezia
globosa, one of the most frequently encountered spe-
cies in the cutis, and demonstrated that this enzyme is
able to hydrolyse the S. aureus’ protein A, thus leading
to counteract the bacterial biofilm formation and
immune evasion, and preserving skin health (Li et al.
2018). Candida albicans is part of the healthy skin myco-
biota, but cutaneous pH level conditions its growth:
hence, any rise in pH, as can readily occur in moist
areas, leads to promote its overgrowth. More specific-
ally, the consequent exaggerated development of C.
albicans, together with S. aureus, plays a pivotal role in
the pathogenesis of the diaper dermatitis (Rippke
et al. 2018).
Human papillomaviruses (HPV) are mainly known for
their capability to cause several tumour types in
humans. What has emerged from a metagenomics
study conducted on 103 healthy individuals is that its
prevalence is 68.9% and it is mainly distributed on the
skin (61.3%), followed by other ecosystems, such as the
vagina, mouth, and gut (Ma et al. 2014). Moreover, this
shotgun sequencing analysis evidenced how the
healthy cutaneous HPV community is more complex
compared to previous evidence measured by the most
used commercial kits which selectively target only
some cervical high- and low-risk genotypes. The
importance of these non-oncogenic viral genotypes is
absolute since they could stimulate or inhibit an HPV
infection by using interference or immune cross-mecha-
nisms and thus represent a guide for the design of new
clinical, epidemiological ex vivo and in vitro studies.
Summarising, the skin protects the human body
from the highly colonised external environment, thanks
to a complex cutaneous microbiota composed by bac-
teria, viruses and fungi that, despite contributing to
people well-being, can be also involved in many benign
and malignant skin disorders.
Therefore, the study of the microbial skin compos-
ition is deepening the knowledge of the microbial spe-
cies that are present during life and their function, by
distinguishing between resident and transient and
what conditions make them able to express their bene-
ficial or pathogenic potential.
In vitro study models
Different approaches, such as culturomic, quantitative
real-time PCR (qRT-PCR), next-generation sequencing
(NGS), mass spectrometry (Maldi-Tof), immunohisto-
chemistry (IHC), Proximity Ligation Assay (PLA) and in
situ hybridisation (ISH) analysis, are useful to obtain
new information to understand how the human skin is
colonised and what is its relationship with the hosted
microorganisms. Swabs, scrapings, tape stripping, hair
follicles, and skin biopsies are commonly used as bio-
logical samples to assess the cutaneous microbiota’s
diversity (Grice et al. 2008; Nakatsuji et al. 2013; Egert
et al. 2017).
Most of the research on the relationship between
dysbiosis and NMSC is indeed based on the results
obtained by the comparative microbiome analysis of
biopsies derived from healthy and diseased individuals.
Through new powerful experimental methods, such as
the NGS, scientists are scanning our microbial ecosys-
tem, revealing an amazing diversity within the body
compartments. Even if these association studies are of
great relevance, however, they cannot distinguish
whether microbiota changes are causes or effects of
tumour development. Conversely, the use of experi-
mental models, with the tuning of the involved factors,
can allow identification of cause-effect relationships
with the highest accuracy. Animal- and advanced 3D
preclinical- models employed in this field will be here
presented.
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Animals
Microbiota’s influence in skin carcinogenesis
processes
One of the main approaches to study the influence of
the microbiota in skin carcinogenesis consists of induc-
ing cancer in mice in the presence or absence of the
microorganism(s) of interest, or its/their derived prod-
uct(s). Skin carcinogenesis can be achieved with phys-
ical (i.e. UV damage or chronic skin trauma), chemical
(i.e. 7,12-dimethylbenz(a)anthracene, DMBA/12-O-tetra-
decanoylphorbol-13-acetate, TPA protocol), or bio-
logical (i.e. HPV infection) agents, or through
genetically engineered mouse models, as excellently
already reviewed elsewhere (Huang and Balmain 2014;
Nguyen et al. 2015). Thus, scientists aiming to study the
microbiota-skin carcinogenesis axis used one of these
well-known protocols, while they were exploring the
role of a given microorganism, or product. For instance,
Weill and collaborators demonstrated the protective
role of lipoteichoic acids (LTA), a cell wall component of
the Lactobacilli, in UV-irradiated female Crl: SKH-1-hrBR
hairless mice (Weill et al. 2013). They observed in LTA-
oral-treated mice, not only a significant delay in tumour
appearance, but also a reversion of the UV-induced
immune suppression, showing higher levels of inter-
feron-c,helper and cytotoxic T-cells in inguinal lymph
nodes. The immunomodulating properties of LTA are
evident since they also increase IgAþ cell number in
the small intestine, as well as activate dendritic cells in
the mesenteric lymph nodes.
Hoste and collaborators investigated the role of flag-
ellin, the main constituent of the bacterial flagella, in
the initial step of two different skin cancer models. By
using a model of wound-induced skin tumour in trans-
genic mice expressing activated MAPK kinase 1 (MEK1),
they found that, besides wound size and inflammatory
infiltrate, the tumour incidence correlated with flagellin
presence, in a Toll-like receptor (TLR)-5 (the bacterial
flagellin receptor)-dependent manner. Similar results
were obtained with the DMBA/TPA carcinogenesis
model, where the knock-down of TLR-5 mice elicited a
substantial tumour development delay (Hoste
et al. 2015).
Some carcinogenic protocols can also combine other
agents, such as the two-stages UV carcinogenesis
model, where SKH-1 hairless mice were treated for
1week with DMBA, followed by UV-B irradiation. During
UV exposure, mice were colonised by a topical applica-
tion of two S. epidermidis’ strains, one producing 6-N-
hydroxyaminopurine (6-HAP), an inhibitor of the DNA
polymerase, and the other not, as control. Interestingly,
they found that the control mice had the expected
higher skin tumour incidence, while the others had a
significantly decreased number of tumours (Nakatsuji
et al. 2018). Furthermore, when applied topically in
UVB-exposed mice, S. epidermidis down-regulated pro-
inflammatory cytokines through the production of
butyric acid (Keshari et al. 2019).
Mice models have been also established to clarify
the mechanisms at the basis of skin tumour develop-
ment upon the combined action of b-HPVs and UV
exposure (Dell’Oste et al. 2008; Rollison et al. 2019;
Tommasino 2019). Tommasino and co-workers devel-
oped a transgenic mouse model expressing HPV38
oncoproteins under the control of the CK14 promoter
to evaluate the potential role of b-HPVs in UV-induced
NMSC (Viarisio et al. 2011). What they observed is that
transgenic mice developed NMSCs after UV exposition,
differently from the wild type ones, whose skin
remained healthy (Viarisio et al. 2017). Therefore, the
authors hypothesised that b-HPV 38 infection maintains
cellular proliferation in UV-stressed cells, through E6
and E7 oncoproteins, in the early stage of skin carcino-
genesis, thus acting as a UV co-factor (Viarisio et al.
2018; Tommasino 2019). Moreover, b-HPVs, similarly to
the mucosal ones, modulate the inflammatory process
and affect the efficiency of host immune surveillance,
helping the infection persistence (Dell’Oste et al. 2008;
Zhou et al. 2019).
Concerning the effect of the Mycobiota, it has been
demonstrated that the injection of C. albicans in hairless
mice induces a delayed-type hypersensitivity similarly
as UV-exposure in humans (Kim et al. 2003); further-
more, BALB/c yeast injected mice have been used to
investigate the effect of sunscreen to prevent the UV-
induced immunosuppression, and thus skin carcinogen-
esis (Chen et al. 2016).
Regarding Malassezia, Perrins et al. evaluated the
presence of the yeast in immunosuppressed neoplastic
cats in which they reported a widespread fungal prolif-
eration in those affected by pancreatic adenocarcinoma
(Perrins et al. 2007). A possible involvement of
Malassezia spp. in skin carcinogenesis has not been pro-
ven yet, although some authors have pointed out on
the overlap between BCC development and Malassezia
location in dogs and cats. The possible role of
Malassezia has been hypothesised to be related to its
production of the Aryl-hydrocarbon receptor (AhR)
ligands. Such substances act on fundamental processes,
such as skin immune tolerance induction, UV carcino-
genesis modulation, increased vitamin D degradation,
metalloproteinase-1 activation, cell proliferation and
senescence inhibition. Importantly, AhR ligands inter-
fere with the Hedgehog pathway, that currently
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represents the main target of BCC therapies (Gaitanis
et al. 2011).
The studies here described, in which animal models
have been used, highlight numerous important func-
tions and the role of microbial structural components
and products in this context.
Skin tumours resistant- and gnotobiotic- animal
models
Another interesting approach consists in the use of skin
cancer highly resistant mice, such as atopic dermatitis
EPI-/- AD models, which are deficient of the barrier pro-
teins envoplakin, periplakin and involucrin (Cipolat et al.
2014). These mice have a defective epidermal barrier,
exhibit a reduction in epidermal cdTCRþ CD3þ cells
(dendritic epidermal T cells, DETCs) and infiltration of
CD4þ T cells into the dermis. Interestingly, they are
highly resistant to develop benign tumours when
treated with DMBA/TPA, the two-stage protocol to
induce at first papilloma and then SCC (Cipolat et al.
2014). Comparing the wild-type with the knock-out
mice, the authors found that EPI-/- ones showed the
same response to DMBA, but a more inflammatory reac-
tion after TPA. They proposed that this intense immune
and inflammatory response could help to prevent
tumour formation. Given the strong connection
between microbiota, inflammation and cancer, scien-
tists further investigated whether the skin microbiota
differs between EPI-/- and wild-type mice (Natsuga
et al. 2016). Despite their failure to demonstrate the
presence of different phyla, they did find three-fold
more abundant and deeper penetrated bacteria in
EPI-/- mice’s skin. However, the bacterial load reduction
did not reduce the atopic features of EPI-/- mice or alle-
viate the T-cell populations abnormalities. The authors
then concluded that the increase in skin microbiota
richness could likely contribute directly to the observed
cancer resistance in this model (Natsuga et al. 2016).
However, the use of skin tumours resistant animal
models in in this context mainly remains an unexplored
area. To support this lack of information, scientists
could take advantage of well-known animals which
possess a different tumour development sensitivity,
such as the TPA-sensitive (i.e. SENCAR, CD-1) and the
TPA-resistant (i.e. C57BL/6J, BALB/c) mice (Hennings
et al. 1993); their microbiota profile could be explored,
eventually gaining new insights underlying their differ-
ent susceptibility.
Another model is represented by gnotobiotic ani-
mals: germ-free (GF) animals, such as pigs or zebra-
fishes, that could be colonised with one or more
specific microorganisms to assess their role in host
physiology (Martın et al. 2016; Melancon et al. 2017;
Hara et al. 2018) and better focus the reciprocal cause-
effect relationship.
Originally obtained via Cesarean-section, GF animals
are now obtained mostly by embryo transfer into GF
surrogate females and maintained in an isolator, where
it is possible to control air, food, and water, which must
be GF too. To study the influence of microbiota in car-
cinogenesis, the tumour is then induced with one or
more selected bacterial strains (Bhatt et al. 2017).
Several studies exploring carcinogenesis, especially
colorectal (CRC), have been made with this mouse
model (Bultman 2014; Bhatt et al. 2017); however, to
the best of our knowledge, there are no scientific stud-
ies on skin keratinocytes carcinogenesis yet.
Animals for deepening the human microbiota-can-
cer connections: some limitations
The use of mice in biomedical research is a longstand-
ing practice, due to the extensive similarities in anat-
omy, physiology and genetics with humans (Abel et al.
2009; Barre-Sinoussi and Montagutelli 2015). Moreover,
low costs, high reproduction rates and a short life span
make them especially appealing. Since the mouse gen-
ome is relatively easy to manipulate, the establishment
of genetically modified mice models greatly facilitates
functional studies, further enhancing the interest.
However, besides the ethical considerations, several pit-
falls are present when biomedical research results are
translated to humans, and the studies on the micro-
biota-cancer axis are no exceptions. For instance, skin
and gut microbiota of mice and humans present some
similarities, but also several differences (Grice et al.
2008; Nguyen et al. 2015). To fill this gap, the research-
ers succeeded in transplanting the human microbiota
in the gnotobiotic mouse model (Goodman et al. 2011;
Hugenholtz and de Vos 2018). Scientists further
improved this model by establishing standardised
microbiota in isobiotic mice, with a stable defined
microbiota that can be easily shared by scientists
(Macpherson and McCoy 2015).
Unfortunately, such studies limitation is that the
crosstalk between microbiota and the host is host-spe-
cific; thus, the observations in mouse models cannot be
translated in humans (Nguyen et al. 2015).
However, despite these limitations, the advantages
they give are still numerous and far surpass other mod-
els (Nguyen et al. 2015). Being aware of this, the results
and conclusions should be made with caution and com-
plemented with new more representative preclinical
models.
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3D Reconstructed skin, microbiota and skin
carcinogenesis
An interesting alternative can be represented by the
three-dimensional (3 D) skin equivalent. Indeed, it con-
sists of a fully differentiated and stratified epidermis
plated onto a collagen or fibrin matrix containing fibro-
blasts, that can realistically represent the structural
characteristics of human skin (Catalano et al. 2013;
Randall et al. 2018). The 3D methodology has been
already validated, especially for HPV-related studies by
several authors (Azzimonti et al. 2009; Borgogna et al.
2012; Squarzanti et al. 2018). They offer several advan-
tages (Rademacher et al. 2018): i) the host specificity is
preserved since keratinocytes and fibroblasts are of
human origin; ii) microbes can be applied onto the epi-
thelial surface to study their interaction with an intact
barrier, or they can be added into the culture medium
to simulate barrier penetration; iii) immune cells can be
integrated into this model; iv) patients’ derived cells
can be used. However, functional studies that use 3D
models to assess the impact of the microbiota on skin
diseases are still rare (Niehues et al. 2018; Rademacher
et al. 2018). In fact, most of the publications in this area
used 3D in vitro skin models investigating the interac-
tions between single microbial species and their host
(Rademacher et al. 2018); thus, there is a strong need to
implement 3D models with human isolated and more
complete microbial communities, in order to closely
reproduce at best the in vivo context. Due to the robust
knowledge of skin carcinogenesis, 3 D co-culture skin
equivalents will allow exploring also this specific area.
Human skin microbiota and NMSC
NMSC is the most common human malignancy, with an
incidence that gradually increases over time (Lomas
et al. 2012). Based on its histopathological characteris-
tics, NMSCs can be classified as BCC or SCC, with a
BCC:SCC ratio of 4:1 in immunocompetent patients.
BCCs rarely metastasise, but they can cause significant
morbidity, as it occurs in sun-exposed areas. On the
other hand, the risk of metastasis from SCC is relevant,
with a 5-year recurrence rate of 8% for high-risk (HR)
lesions and a poor long-term prognosis for metastatic
patients (Barton et al. 2017). Actinic keratosis (AK) rep-
resents another kind of NMSC frequent among people
with fair skin and previous strong sun-exposure.
Although the potential capability of AK to transform
into SCC is universally accepted, the pivotal factor lead-
ing to its progression has not yet completely under-
stood. Bowen’s disease is a further NMSC type as it
consists of an in-situ SCC. In any case, NMSCs constitute
a significant economic burden for the Health Service
(Duarte et al. 2018).
The risk factor most closely related to the onset of
NMSC is represented by UV chronic exposure, which
explains the increased incidence of these neoplasms in
elderly people (Surdu et al. 2013). Accordingly, some
changes in microbiota composition (also in the gut)
after UVB exposure have been recently demonstrated
(Bosman et al. 2019; Yuan et al. 2020). However, a fun-
damental role is also played by immunologic surveil-
lance, as demonstrated by the higher risk of NMSC and
poor prognosis in chronically immunosuppressed
patients, such as solid organ transplant recipients
(Howard et al. 2018; Zavattaro et al. 2019) or those
affected by rheumatic diseases (Diernaes et al. 2019).
The ability of the immune system to counteract skin
carcinogenesis has been recently elucidated by
Strickley et al. They demonstrated that immunity
against some commensal HPVs protects from UV-
induced skin cancer in mice, and they supposed that a
similar process could occur in humans (Strickley et al.
2019). Nevertheless, the role of the cutaneous micro-
biota both in the direct skin carcinogenesis and in the
modulation of the immune system still needs to be
clarified (Figure 2). Human microbiota alterations have
been recently linked to different cancer types (such as
colorectal, pancreatic, head and neck, and lung), several
benign and malignant skin disorders (Chen et al. 2017),
with more than 15% of all caused by infections (Martel
et al. 2012). Similarly, a recent study by Mrazek et al.
has reported significant differences in microbiota com-
position among healthy skin and melanoma in a pig
model (Mrazek et al. 2019).
Furthermore, a worsening role in cancer has been
suggested for antibiotics. Indeed, they may influence
the microbiota composition and may promote a state
of chronic inflammation, leading to an altered immune
response against cancer. In fact, bacterial dysbiosis
induced by repeated antibiotic courses has been corre-
lated to cancer development, mainly in gastro-intestinal
and lung neoplasms (Boursi et al. 2015), since they
decrease the efficacy of immune checkpoint inhibitors
in patients with advanced cancers (Rossi et al. 2019).
Concerning NMSC, a study conducted by Kullander
et al. on lesional skin of patients affected by AK, sebor-
rhoeic keratosis (SK) and SCC and on normal skin biop-
sies of control subjects, allowed to highlight how S.
aureus can be strongly associated both to AK and SCC
(Kullander et al. 2009). Specifically, through a PCR ana-
lysis in which the S. aureus nuc gene was amplified, it
was found that the presence of this bacterium is
strongly associated with SCC (29.3% positive samples)
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with a probability ratio (odds ratio, OR) SCC/healthy
skin of 6.23 (5.7% of positive samples). The study also
showed an association of S. aureus with AK (12.3%), but
not with SK (1.4% positivity).
The same analysis, performed on skin swabs from
tumour and healthy skin, gave similar results (OR SCC/
healthy skin: 2.67). The limitation of this experimental
design was that it doesn’t identify whether this associ-
ation implies a direct influence of S. aureus on the car-
cinogenic process or not (Balkwill and Mantovani 2001).
A possible mechanism that explains this open question
is given by the ability of this bacterium to induce a
state of chronic inflammation (Balkwill and Mantovani
2001) that is mediated by cytokines release (Aggarwal
et al. 2006). S. aureus, through the virulence peptide
called modulin (Nakagawa et al. 2017), induces the
release of IL-1a and IL-36a by keratinocytes and the sig-
nalling pathway mediated by these cytokines is
required for the release of IL-17 by cd T cells. This pro-
inflammatory cytokine, together with IL-22 and TNF
alpha, in turn regulates the cutaneous colonisation of
S. aureus by triggering a self-maintenance inflammation
mechanism. All these molecules have a key role in trig-
gering the tumour progression since they induce both
the proliferation and metastatic migration of skin can-
cer cells.
Based on the evidence that AKs can progress or
regress over time (Chen et al. 2013), a longitudinal and
transversal survey carried out on a cohort of AK and
SCC lesions of immunocompetent subjects prone to the
development of NMSC and non-photodamaged con-
trols (Non-Lesional Controls, NLC), was conducted in
2019 by Wood et al. (Wood et al. 2018). The study was
carried out on skin swabs taken once a month, for
5months, from the forearms of subjects who didn’t
receive antibiotics in the previous 3months and with at
least 3-5 AK lesions and a previous SCC history.
Patients’ clinical history allowed to establish 5months
as a enough time span for the progression to SCC of
some AK lesions. Sequencing of the V3 variable region
of the 16S rRNA gene showed that Propionibacterium
and Malassezia are relatively more abundant in healthy
Figure 2. Skin microbiota changes during the pathogenesis of NMSC.
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perilesional skin regions and confirmed that
Staphylococcus is the most represented genus both in
AK and in SCC, with a predominance of the S. aureus
species (Figure 1). Specifically, 11 Operational
Taxonomic Units (OTUs) of S. aureus were identified in
the enrolled subjects; 6 of these were significantly asso-
ciated with SCCs, with OTUs 50 and 216 present in all
the study patients, suggesting their specific involve-
ment in progression from AK to SCC (Wood et al. 2018).
This datum has been recently confirmed by the taxo-
nomic analysis made via a 16S rRNA gene-based micro-
bial profiling and sequencing by Madhusudhan et al.
(Madhusudhan et al. 2020). They reported S. aureus
overabundance in SCC and AK compared with BCC
samples. Accordingly, since Malassezia was decreased
in SCCs, it has been supposed that this yeast could be
potentially protective against S. aureus over-colonisa-
tion (Kullander et al. 2009; Madhusudhan et al. 2020).
Moreover, as far as back as Wanke et al. showed how
keratinocytes mediated AMPs production is differen-
tially regulated by these commensal and aggressive
Staphylococci, which synergistically and respectively
switch on or not the NF-kB pathway (Wanke et al.
2011). While hBD-1 is normally present in skin, others
AMPs, such as hBD-2, hBD-3 and RNase7 are modulated
by microorganisms. The most studied AMPs are pre-
cisely those induced by S. aureus; in fact it stimulates
the overexpression of hBD2 by keratinocytes in a site-
and age-dependent way (Madhusudhan et al. 2020).
This cationic protein, working together with hBD3,
cethelicidins, lysozyme and the Esp serine protease,
provides a prompt and almost complete clearance from
S. aureus.
Besides S. aureus, other bacteria, such as
Staphylococcus epidermidis, Escherichia coli and
Pseudomonas aeruginosa, induce hBD2 (Dinulos
et al. 2003).
As also depicted by Niyonsaba et al. AMPs in turn
stimulate keratinocytes to produce proinflammatory
cyto- and chemo-kines, that therefore participate in
the remarkable trigger of their proliferation and
migration, mediated by EGFR, STAT-1 and 3, events
that underlie the tumorigenesis process (Niyonsaba
et al. 2007).
This was confirmed by Madhusudhan et al. in co-cul-
ture studies (Madhusudhan et al. 2020); in fact S. aureus
overgrowth in SCC has been significantly associated
with an high increase of hBD-2 and tumour cell prolifer-
ation. These events suggest that S. aureus might pro-
mote tumour cell growth by modulating the specific
expression of this AMP, thus emphasising their
intercorrelation.
Overall these studies and those of Brandwein et al.
clearly underline how the insights on the role of cuta-
neous AMPs against specific microbial species are open-
ing the possibility to understand how host-microbiota
dynamics within the skin compartments are orches-
trated and how an altered AMP milieu correlates with
selective skin dysbiosis (Brandwein et al. 2017).
If, as emerged, strains of S. aureus contribute to the
genesis of the cutaneous carcinogenic process also
through the promotion of a chronic inflammatory state,
they could serve as markers of risk for the development
of SCC; therefore, lesions with persistent infection could
be ideal candidates for monitoring and interventional
treatments. It could also be assumed that the high inci-
dence of SCC observed in immunosuppressed patients
could be related to the inability of the immune system
to control specific SCC microbial triggers (Figure 2).
Another cutaneous disease characterised by chronic
inflammation is Hidradenitis Suppurativa (HS), a recur-
rent and chronic disease involving the apocrine glands
of the axillary, perineal, perianal and genital regions. It
is characterised by a frequent relapse of swollen and
painful abscess lesions leading to scarring and fistulae
formation. HS has been linked to a 4.6-fold increased
risk of NMSC development, mainly represented by SCC,
which usually arise many years after the disease onset
(Kohorst et al. 2015). Once again, the presence of bac-
teria such as S. aureus, S. pyogenes, and P. aeruginosa
that are responsible for a chronic inflammatory state
and suppurative recurrences, has been argued to be
causative for SCC development (Samaras et al. 2010).
Hence, in summary, once the microbiota’s balance
has been disturbed, it promotes chronic inflammation
through Th17 activation and T-reg stimulation, thus
promoting carcinogenesis. Therefore, a direct crosstalk
between the skin-microbiota and the immune system
does exist (Iannitti and Palmieri 2010; Yu et al. 2015).
Iida et al. demonstrated that the microbiota can also
influence the tumour microenvironment. Their experi-
mental model evaluated the response of mice, either
germ-free or antibiotic-treated, transplanted with
tumour lines (melanoma, colon carcinoma, and lymph-
oma) and subsequently submitted to immunotherapy
and chemotherapy. The result was consistent with a
better outcome of therapy in the presence of a healthy
host-microbiota balance, with a decrease in the activa-
tion of pro-inflammatory genes and cytokines, as well
in Reactive Oxygen Species (ROS). Based on such
results, the authors concluded that an intact com-
mensal microbiota is required for optimal response to
cancer therapy (Iida et al. 2013). Accordingly, Sivan
et al. have investigated the efficacy of anti-PD-L1
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treatment in melanoma mice model, and they found
that the animals fed with Bifidobacterium spp. showed a
better response, thus showing an improved capability
to control tumour through the immune system (Sivan
et al. 2015). Similarly, it has been demonstrated that
oral supplementation with Akkermansia muciniphila in
humans was able to ameliorate the outcome in patients
treated with anti-PD-1 immunotherapy for melanoma,
renal carcinoma, and lung cancer (Routy et al. 2018).
Also, the effect of other potential carcinogenic fac-
tors (i.e. UV radiation) may surely contribute to further
facilitate the onset of cancer (Yu et al. 2015).
Among viruses, both HPV and Epstein-Barr (EBV)
interfere into epithelial cancer progression and metasta-
tization processes (Chen et al. 2016; Cyprian
et al. 2018).
Regarding HPV infection, an in situ RNA and DNA
hybridisation analysis evidenced a significant reduction
of the viral activity and load of 25 commensal b-HPVs in
cancer biopsies of NMSC affected patients respect to
the adjacent healthy skin of the same subjects, suggest-
ing a very high immune selection against HPV-infected
tumoral keratinocytes. In fact, following the protection
by the T cell immunity, commensal b-HPVs can protect
immunocompetent hosts from skin cancer develop-
ment. Conversely, when the immunity is lost or com-
promised together with HPV oncogenicity itself, the
skin cancer risk increases by100-fold in immunocom-
promised patients (Strickley et al. 2019).
Moreover, the recent article of Tommasino strongly
states that b-HPVs, mainly HPV38 genotype in trans-
planted patients, maintain the proliferative status of
UV-damaged keratinocytes, thus enhancing the great
attitude of these immunodeficient people towards
tumorigenesis (Tommasino 2019). This supports once
more the role of UV rays as NMSC drivers with beta-
HPVs as partners in favouring the UV-induced DNA
mutations accumulation.
EBV is a DNA virus belonging to the Human Herpes
Virus (HSV) family, mainly known for its relationship
with Burkitt’s lymphoma and post-transplantation lym-
phoproliferative diseases (PTLD). Concerning epithelial
neoplasms, it has been associated with gastric cancer
and the quite rare nasopharyngeal carcinoma (NPC),
which is frequently observed among subjects from
Southern China, Indonesia and North Africa. In fact, EBV
downregulates, through the latent membrane oncopro-
tein-1 (LMP-1) and E-cadherin expression, the activation
of signalling pathways such as those of PI3K/Akt and
MAPK, while upregulates PD-L1 in NPC-derived cells via
the STAT3, AP-1 and NF-KB signalling (Fang et al. 2014;
Cyprian et al. 2018; Outh-Gauer et al. 2018). Moreover,
44 mature EBV miRNAs have been identified as related
to epithelial-mesenchymal transition (EMT) and cancer
progression (Skalsky and Cullen 2015).
Data concerning possible involvement of the myco-
biota in NMSC development in humans are currently
lacking. On the other hand, the increased risk of cutane-
ous infection by opportunistic fungi, as well as yeast
overgrowth in the course of immunosuppression is well
known. Indeed, chemotherapy agents are responsible
for epithelia damage, either in the gut or in the skin,
and this could allow the penetration of fungi and yeasts
(Teoh and Pavelka 2016). Similarly, radiotherapy depicts
an important risk factor for skin infections, and, among
fungi, the most encountered pathogens are repre-
sented by Candida species (Altoparlak et al. 2011;
Moqbil and Kurnatowski 2012).
In the nation-wide population-based study by Chung
et al. the presence of Candida infection resulted associ-
ated to a higher risk of cancer, mainly haematologic
malignancies, of the head and neck, pancreas, skin and
thyroid. Although the Authors underlined the role of
the yeast in promoting cancer as a consequence of
their proinflammatory impact in the tumour microenvir-
onment, they also speculated that patients suffering
from candidiasis are supposed to seek for a dermato-
logical visit more frequently and, consequently, skin
cancer should be easily diagnosed (Chung et al. 2017).
Moreover, the response of Malassezia spp. to
Photodynamic Therapy (PDT) has been reported in
patients affected by NMSCs. PDT induced a decrease in
Malassezia in the peritumoral skin, in accordance with
the therapeutic use of PDT in certain fungal skin infec-
tions (Calzavara-Pinton et al. 2012; Gilaberte
et al. 2015).
How to influence the microbiota?
As stressed, the skin and gut microbiota play a very
important role in conditioning the susceptibility and
the development of numerous diseases, either cutane-
ous or affecting other organs. Since healthy microbiota
may have a protective effect on numerous pathological
conditions, the following questions arise: “How to pre-
serve our microbiota?” and, in the case of dysbiosis
and/or microbiota alterations,” How to restore it?” Once
again, the answer is represented by microorganisms,
and, in detail, mainly by bacteria.
Since many years, specific bacterial strains have been
used to counteract different diseases, ranging from
diarrhoea to some cancer types. Indeed, the Bacillus
Calmette-Guerin vaccine (BCG), represented by a spe-
cific Mycobacterium bovis strain, has been administered
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for a long time against superficial bladder cancer
(Schellhammer et al. 1986). The rationale for its use was
its capability to modulate inflammation and maintain a
correct immune system function (Von Hertzen et al.
2011; Sherwani et al. 2018). The cell wall skeleton of
BCG, in fact, induces the CD4þ T cell subset and stimu-
lates the differentiation from the naïve to memory
phenotype, giving promising clinical effects in the adju-
vant immunotherapy for cancer (Nishida et al. 2019).
BCG, administered alone or in combination with dacar-
bazine and/or autologous tumour cell vaccine,
improves the survival of metastatic melanoma affected
patients (Lotem et al. 2002; Triozzi et al. 2011; Sloot
et al. 2016; MMAIT-IV Clinical Trial Group 2017).
In more recent years, the terms “prebiotics” and
“probiotics” have been coined to indicate exogenous
substances able to interfere positively with the human
microbiota, and namely keep it healthy and/or restore
it. In detail, “prebiotics” include a class of non-digestible
food ingredients that can selectively stimulate the
growth and/or activity of beneficial microorganisms,
such as bacteria and fungi. On the contrary, “probiotics”
are live bacteria and yeasts that exert health benefits to
the host, mainly by restoring the gut microbiota
(Krutmann 2012). The most common beneficial pro-
biotic strains belong to the Lactobacilli and
Bifidobacteria genera.
Both pre- and pro-biotics selectively stimulate the
growth of microorganisms in the large bowel, thus
leading to different beneficial effects. Their simultan-
eous use is referred as “synbiotics” (Musthaq
et al. 2018).
The administration of oral probiotics has demon-
strated to be safe and beneficial against numerous con-
ditions. Indeed, they are currently used in the
management of digestive symptoms and diseases (i.e.
diarrhoea, inflammatory bowel disease), but also in
atopic dermatitis, acne, psoriasis, bacterial vaginosis,
genital candidiasis, reduction of serum cholesterol level
and so on (Russell et al. 2011; Kumar et al. 2014).
The main mechanisms through which probiotics
exert their benefits onto the skin reside in their immu-
nomodulatory capabilities (Wie€ers et al. 2019). When
administered orally, they exert their action at the gut
level, thus leading to influence immune responses in
other tissues (i.e. the skin). Furthermore, they can also
act as antioxidants and, when applied topically, they
can provide a protective barrier towards exogenous fac-
tors and compete with other cutaneous microorgan-
isms in order to restore the healthy resident microbiota
(Rahmati Roudsari et al. 2015; Maguire and Maguire
2017; Knackstedt et al. 2020).
The role of probiotics in NMSC
To date, despite many papers have supported the use
of probiotics in several inflammatory cutaneous dis-
eases (Szanto et al. 2019; Yu et al. 2020), only a few
have investigated their possible application in skin can-
cer, either for chemoprevention or therapy purposes.
Some of these have evaluated the possibility of the
oral administration of Lactobacillus strains in order to
evaluate their photoprotective effect. As mentioned,
Weill et al. have studied the effect of LTA from L. rham-
nosus GG in hairless mice that were UV-irradiated daily
for 20 consecutive days. A tumour development delay,
mediated by a transitory increase in cytotoxic and
helper T-cells in the draining lymph nodes, was
observed (Weill et al. 2013). More recently, LTA from
the same strain was discovered to be able to overcome
the immunosuppressive effect of UVB and impair SCC
growth once the irradiation is suspended (Friedrich
et al. 2019). The UV effect on bacteria has also been
previously studied by Wang et al. that measured the
porphyrin level produced by P. acnes after inoculation
in mice’s ears. They observed that bacteria are respon-
sive to UVB and c-rays with a reduction in porphyrin
production, and a consequent variable effect on protein
oxidation-deoxidation, depending on the radiation
type. Since porphyrin concentration in irradiated P.
acnes may decrease before the skin damage is
detected, the authors concluded that it could act as a
biomarker and as a clue for radiation risk (Wang
et al. 2012).
As previously mentioned, Nakatsuji et al. adminis-
tered a specific S. epidermidis strain, either topically or
intravenously in mice, and showed its antiproliferative
effect mediated by 6-HAP. This molecule was produced
by a common commensal strain of S. epidermidis able
to suppress the tumour growth in vivo by more than
60% when given intravenously. Furthermore, UV-irradi-
ated SKH-1 hairless mice topically treated failed to pro-
duce squamous tumours (Nakatsuji et al. 2018).
In a further randomised, double-blind placebo-con-
trolled clinical trial on probiotics, Lactobacillus johnsonii
NCC 533 (Lal) was administered to healthy human vol-
unteers before UV-exposure and, subsequently, the
inflammatory cells were evaluated through skin biopsy
analysis. In treated patients, CD36þ monocytic cells dis-
appeared (their differentiation in Langerhans cell pre-
cursors is supposed) and recovery of basal CD1aþ cell
staining was also detected. Such results highlighted a
protective effect of Lal against immunosuppression due
to UVB-irradiation (Peguet-Navarro et al. 2008;
Gueniche et al. 2009). In a similar way, the oral adminis-
tration of L. johnsonnii plus carotenoids prior to sun-
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exposure in healthy women, showed to prevent the
UV-induced Langerhans cells decrease and help to
restore the immune system homeostasis. Furthermore,
the Minimal Erythema Dose (MED) was increased by
19% in patients receiving oral probiotics (Bouilly-
Gauthier et al. 2010).
Finally, in the study by Lee et al. the administra-
tion of the Maesil fruit extracts fermented with probi-
otics (Saccharomyces cerevisiae from Korea Collection
for Type Cultures (KCTC) 7928, Bacillus subtilis from
KCTC 1666, and Lactobacillus acidophilus from KCTC
3155) in different concentrations (1% and 2%)
resulted to be associated with papilloma’s reduction
in skin carcinogenesis-induced mice. This reduction
was statistically significant and more represented in
mice fed with 2% probiotics fermented Maesil. The
authors concluded that this mix might have an
important role in skin carcinogenesis control (Lee
et al. 2013). Nevertheless, in our opinion, the effect
of probiotics in such experimental setting should be
carefully discussed.
Accordingly, since the probiotics’ market is not har-
moniously regulated among countries and since the dif-
ferences in their efficacy and safety mainly depend on
the diversity of the microorganisms sold, their off-trial
use in patients with cancer has been discouraged
(McQuade et al. 2019). Furthermore, in Europe at least,
cosmetics by regulation can’t include more than 1000
live germs per gram, thus impeding the use of loved
probiotics in this category as well. Therefore, the topical
application should be carefully evaluated in order to
establish their therapeutic role against skin cancer and
hopefully favour their employment in this context (Lee
et al. 2019).
Conclusion
Overall this review highlights some important key
points on skin microbiota community research: cutane-
ous commensal microorganisms adapt and use host’s
epithelial surface nutrients, produce antimicrobial pep-
tides, orchestrate the innate and adaptive epithelial
immune system to inhibit pathogens colonisation, and
maintain a healthy epithelial status possibly also when
exogenous and endogenous perturbations occur.
Moreover, thanks to NGS and in vitro study models, it
will be likely possible to identify specific OTUs that
could be ascribed as NMSC progression signatures and
as instruments for better a management of this skin
malignancy.
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